Cellectis to Report Third Quarter 2025 Financial Results

Cellectis S.A., a clinical-stage biotechnology company, announced that it will report its financial results for the third quarter of 2025 on November 7, 2025, after the close of the US market. The press release will be available on the company's website in the Investors section. Cellectis will not host a conference call to discuss these results, but the investor relations team will be available for questions. Cellectis is known for its pioneering gene-editing platform, which it uses to develop life-saving cell and gene therapies. The company focuses on an allogeneic approach for CAR T immunotherapies in oncology and has in-house manufacturing capabilities, making it one of the few end-to-end gene editing companies.